IMAGION BIOSYSTEMS LIMITED — Call Transcript 2017

W H E R E B I O T E C H N O L O G Y & N A N O T E C H N O L G Y M E E T

==> picture [113 x 38] intentionally omitted <==

ASX Announcement 6 December 2017

Investor conference call

MELBOURNE — 6 December 2017 — Imagion Biosystems Limited ( Imagion , ASX:IBX) invites shareholders and other interested parties to join CEO Robert Proulx for an update on the Company’s progress and developments.

Mr Proulx will also address questions from investors as part of the call. Please submit these by email to [email protected] in advance of the date of the call.

The call is scheduled for Tuesday 12 December 2017 at 12:00pm AEDT (9am AWST / 5pm US Pacific time Monday 11 December).

To connect to the call please use either the following weblink to register or join using one of the dial-in numbers and access code:

WEBLINK: https://attendee.gotowebinar.com/register/6343257790064495618

DIAL-IN:

Australia

Long distance +61 2 9087 3602 Toll-free 1 800 071 059

United States

Long distance +1 (213) 929 4221 Toll-free 1 877 309 2074

United Kingdom

Long distance +44 330 221 9914 Toll-free 0 800 169 0433

ACCESS CODE: 168-007-394

About Imagion Biosystems

Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSense[TM] technology, the company has the potential to optimise patient care and reduce mortality rates across various cancer indications. Based in Albuquerque, New Mexico, Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please contact:

[email protected] or [email protected]

Imagion Biosystems Limited ACN 616 305 027 Level 8, 555 Bourke Street, Melbourne VIC 3000 www.imagionbiosystems.com